BioMarin Pharmaceutical Inc. (BMRN) News
Filter BMRN News Items
BMRN News Results
|Loading, please wait...|
BMRN News Highlights
- For BMRN, its 30 day story count is now at 28.
- Over the past 27 days, the trend for BMRN's stories per day has been choppy and unclear. It has oscillated between 1 and 13.
- The most mentioned tickers in articles about BMRN are GENE, RARE and NIO.
Latest BMRN News From Around the Web
Below are the latest news stories about Biomarin Pharmaceutical Inc that investors may wish to consider to help them evaluate BMRN as an investment opportunity.
BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral and three poster presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A at the American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting being held May 11-14. These six presentations advance the scientific understanding of the potential of valoctocogene roxaparvovec to treat people with hemophilia A.
Evercore ISI Stick to Their Buy Rating for BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of BioMarin...
Biotechnology company BioMarin Pharmaceutical (BMRN) posted 1Q results that beat analysts' estimates. Revenue decreased 3.2% year-on-year to $486 million but came in $39.65 million ahead of consensus forecasts. GAAP earnings per share came in at $0.09 versus analysts’ estimates for a $0.10 loss. The decrease in revenue was mainly attributable to generic competition leading to a 42% year-on-year drop in sales of Kuvan to $70.8 million, which was partially offset by a 56% year-on-year jump in Palynziq sales to $54 million.
BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.
Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, such as 10-Q, 10-K, and 8-K report.
BioMarin Pharmaceutical (BMRN): Q1 GAAP EPS of $0.09 beats by $0.19.Revenue of $486M (-3.2% Y/Y) beats by $39.65M.Non-GAAP net income of $170M-$220M. Press Release...
The FDA has extended the PDUFA date for BioMarin's (BMRN) short stature treatment vosoritide by three months to November 20, 2021, to review two-year phase 3 data.Data from that extension study presented last month demonstrated the long-term benefit of vosoritide in treating achondroplasia.Updated data from a phase 2 extension study presented earlier...
BMRN stock is consolidating on light volume prior to earnings. The company is projected to report earnings and revenue that are lower on a year-over-year basis. With a potential upside of over 46%, that could make BioMarin an attractive buying option.